Get startedLog in
    Picture of Rafael Holdings logo

    RFL — Rafael Holdings News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareAdventurousSmall CapNeutral
    All News

    Brief: Rafael Pharmaceuticals Crosses Enrollment Of 150 Patients In Pivotal Phase 3 Trial Of Cpi-613 For Relapsed Or Refractory Acute Myeloid Leukemia

    Picture of Rafael Holdings logoRafael Holdings
    30/03/2021 14:07
    March 30 (Reuters) - Rafael Holdings Inc  RFL.N :
    * RAFAEL PHARMACEUTICALS CROSSES ENROLLMENT OF 150 PATIENTS
IN
PIVOTAL PHASE 3 TRIAL (ARMADA 2000) OF CPI-613® (DEVIMISTAT) FOR
RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML)

Source text for Eikon:  ID:nGNX3x4WT4 
Further company coverage:  RFL.N 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Rafael Holdings

    See all news